DermaMedics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DermaMedics - overview
Location
Oklahoma City, OK, US
Primary Industry
Healthcare Specialists
About
DermaMedics is a skincare company specializing in innovative products designed to enhance skin health through science-driven formulations. Their offerings focus on addressing various skin concerns with advanced biochemistry. DermaMedics develops specialized skincare solutions, primarily silicone-based serums enriched with patented natural antioxidants. The company was founded by Bryan Fuller, who has a background in skin biochemistry.
The firm is headquartered in Oklahoma City, US. In March 2012, DermaMedics raised USD 1. 5 mn in VC funding from i2E Inc. , marking its sole investment round to date, resulting in total funding of USD 1.
5 mn. Dermamedics specializes in skincare products rooted in extensive research on skin biochemistry, conducted by its founder, Dr. Bryan Fuller. The company's flagship offerings are silicone-based serums that incorporate patented natural antioxidants, addressing skin concerns such as inflammation and aging.
These products aim to improve skin structure and function through the benefits of hormones and natural anti-inflammatory compounds, serving individual consumers across North America, Europe, and Asia. Dermamedics generates revenue through direct-to-consumer sales of its skincare products via an e-commerce platform. The brand offers personalized product recommendations to optimize customer engagement and retention. Pricing for their flagship silicone-based serums is competitive within the market, reflecting the extensive research involved in their development, contributing to the company’s financial performance in the skincare industry.
DermaMedics plans to expand its product line with upcoming launches of new formulations aimed at various skin concerns, with releases anticipated in the near future. The company is also targeting expansion into additional markets in Europe and Asia by the end of 2023. The recent funding of USD 1. 5 mn raised in March 2012 will be utilized to support these growth initiatives, including product development and market entry strategies.
Current Investors
i2E Inc.
Primary Industry
Healthcare Specialists
Sub Industries
Dermatology, Pharmaceutical Research & Development
Website
www.dermamedics.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.